BAXERNA

Baxerna develops next-generation bacterial mRNA vaccines targeting Mycobacterium tuberculosis, Mycobacterium ulcerans, and Acinetobacter baumannii.

Baxerna is developing a bacterial vaccine pipeline using mRNA technology against three facultative intracellular pathogens. The company uses immunopeptidomics to discover bacterial antigens, develops novel mRNA formulations, and integrates innovative production methods for local manufacturing and cost optimization.